Zota Health Care Ltd. (ZOTA) AI Stock Analysis

• Market Cap: ₹33.15B
• Dividend Yield: 0.06%
• Average Volume (3M): 68.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: 82.58%
• EPS Growth: -63.05%
• Country: IN
• Employees: 445
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -8.90
• Shares Outstanding: 30,332,655
• 10 Day Avg. Volume: 83,032
• 30 Day Avg. Volume: 68,228
• PEG Ratio: -0.15
• Price to Book (P/B): 10.00
• Price to Sales (P/S): 7.63
• P/FCF Ratio: -23.31
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -35.7
• Revenue Forecast (FY): ₹5.71B

• Rating: 41 Neutral
• Price Target: ₹1,071.00 ▼(-30.15% Downside)
• Action: Reiterated Date: 01/23/26
• Date: Action: Reiterated 01/23/26

The score is weighed down primarily by weak financial performance—loss-making operations and negative operating/free cash flow despite strong revenue growth. Technicals add further pressure with price below key moving averages and a negative MACD. Valuation is mixed: a high dividend yield helps, but a negative P/E reflects ongoing losses.

Positive Factors

Strong Revenue Growth

Sustained high revenue growth indicates expanding product adoption and distribution reach. Over a 2–6 month horizon this growth provides a structural runway to achieve scale, dilute fixed costs, and fund investments that, if sustained, can support a durable move toward profitability once operating efficiency improves.

High Gross Margin

A gross margin above 50% points to strong unit economics and pricing power in core formulations. This margin buffer supports long-term sustainability by absorbing input cost volatility and permitting reinvestment into sales, R&D, or manufacturing scale, enabling lasting competitive positioning if operating costs are controlled.

Balanced capital base and asset growth

A roughly balanced equity share and growing asset base create structural capacity to expand production or enter new markets. This capital structure, coupled with tangible assets, gives management optionality to support durable growth initiatives and scaling efforts without immediate dilution, assuming profitability trends improve.

Negative Factors

Negative Profitability

Persistent operating losses undermine the company’s ability to self-fund growth and erode returns to equity holders. Over months this structural profitability gap increases dependence on external financing, limits reinvestment capacity, and heightens execution risk unless cost structure or revenue mix improves materially.

Negative Operating & Free Cash Flow

Ongoing negative operating and free cash flows signal weak cash generation and working capital pressure. This durable liquidity shortfall forces reliance on external financing, constrains capex and commercialization spending, and raises the risk that cash needs will hamper strategic initiatives over the medium term.

Moderate Leverage

A debt-to-equity ratio near 0.6 combined with negative profits and cash flow reduces financial flexibility. Durable leverage pressure increases interest and refinancing risk, potentially diverting cash from growth or margins improvement efforts and limiting the firm's ability to withstand operational setbacks over several months.

Zota Health Care Ltd. Business Overview & Revenue Model

Company Description

Zota Health Care Limited develops, manufactures, and markets pharmaceutical products in India. It offers generic drugs, over-the-counter products, ayurvedic products, and nutraceutical products. The company provides various medicines for chronic illnesses, including heart disease, diabetes, thyroid, and others. As of March 31, 2021, it operated 591 retail stores under the DAVAINDIA name in 24 states of India. The company was founded in 1995 and is headquartered in Surat, India.

How the Company Makes Money

Zota Health Care primarily makes money by selling pharmaceutical products and related healthcare offerings to distributors, hospitals, pharmacies, and other institutional/retail channels in India and in export markets. Key revenue streams typically include (1) sales of branded/generic formulations marketed under the company’s own portfolio, (2) contract/third-party manufacturing (if applicable in its operating model) where it earns manufacturing fees or product sale margins for producing formulations for other marketers, and (3) export sales where revenue is generated from international distribution/market access. The company’s earnings are driven by product volumes, pricing/margins, therapeutic mix, manufacturing utilization, regulatory approvals for markets served, and the strength of its distribution network and channel partners. Specific details on product-line contribution, major partnerships/customers, and the split between domestic sales, exports, and contract manufacturing are not available here and are therefore null.

Zota Health Care Ltd. Financial Statement Overview

Summary

Despite strong revenue growth (62.3% from 2024 to 2025), profitability is weak with a -19.2% net margin and negative EBIT/EBITDA margins. Balance sheet leverage is moderate (debt-to-equity 0.62) but ROE is negative, and cash flow is a key concern with negative operating cash flow and free cash flow.

Income Statement

Zota Health Care Ltd. has seen significant revenue growth from 2024 to 2025, with a revenue growth rate of 62.3%. However, the company is facing profitability challenges with a negative net profit margin of -19.2% and a gross profit margin of 53.1% in 2025. Negative EBIT and EBITDA margins further highlight operational inefficiencies, impacting overall profitability.

Balance Sheet

The company has a moderately high debt-to-equity ratio of 0.62, indicating reliance on debt financing. Despite this, the equity ratio is relatively stable at 50.9%, suggesting a balanced capital structure. Return on equity is negative, reflecting ongoing profitability issues. The company's asset base has grown, which could support future expansion if profitability improves.

Cash Flow

Negative free cash flow and operating cash flow indicate liquidity challenges, with a significant free cash flow decline from the previous year. The company has a negative free cash flow to net income ratio, suggesting cash generation issues. Financing activities have been used to support operations, raising concerns about sustainability.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.98B	2.93B	1.80B	1.40B	1.31B	1.07B
Gross Profit	1.09B	1.56B	803.38M	310.68M	418.86M	193.14M
EBITDA	58.61M	-36.65M	81.21M	98.05M	164.26M	28.63M
Net Income	-475.21M	-563.98M	-143.48M	-57.73M	89.08M	-2.09M
Balance Sheet
Total Assets	6.06B	4.39B	2.28B	1.58B	1.39B	854.69M
Cash, Cash Equivalents and Short-Term Investments	63.18M	36.19M	10.05M	11.15M	22.99M	13.46M
Total Debt	1.81B	1.40B	952.85M	451.22M	149.00M	0.00
Total Liabilities	2.87B	2.12B	1.38B	777.55M	494.67M	191.72M
Stockholders Equity	3.16B	2.24B	899.77M	803.57M	896.27M	662.97M
Cash Flow
Free Cash Flow	-558.29M	-959.42M	-226.94M	-145.05M	100.84M	-28.18M
Operating Cash Flow	-191.07M	-499.64M	-59.84M	-20.06M	133.32M	-8.90M
Investing Cash Flow	-728.26M	-956.20M	-129.03M	147.03M	-266.52M	38.20M
Financing Cash Flow	946.32M	1.47B	187.76M	-138.81M	142.73M	-24.19M

Zota Health Care Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1533.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ZOTA, the sentiment is Negative. The current price of 1533.2 is above the 20-day moving average (MA) of 1236.35, above the 50-day MA of 1312.67, and above the 200-day MA of 1342.53, indicating a bearish trend. The MACD of -57.25 indicates Positive momentum. The RSI at 23.98 is Positive, neither overbought nor oversold. The STOCH value of 12.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ZOTA.

Zota Health Care Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALEMBICLTD	74 Outperform	₹20.45B	10.80	―	2.36%	16.53%	4.37%
SMSPHARMA	70 Outperform	₹34.24B	29.96	―	0.13%	11.91%	36.92%
SOLARA	54 Neutral	₹20.84B	-36.05	―	―	-4.18%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PANACEABIO	51 Neutral	₹19.43B	144.78	―	―	9.78%	50.78%
INDOCO	49 Neutral	₹17.50B	-18.14	―	0.08%	-2.81%	-444.69%
ZOTA	41 Neutral	₹33.15B	-40.91	―	0.06%	82.58%	-63.05%

Zota Health Care Ltd. Corporate Events

Zota Health Care Schedules Investor Meeting with Nirmal Bang

Zota Health Care Ltd. has announced that its officials will participate in an analyst and institutional investor conference organized by Nirmal Bang Institutional Equities on March 6, 2026, via video conference. The company will use existing business update presentations already available in the public domain and has clarified that no unpublished price-sensitive information will be disclosed during these meetings, underscoring its adherence to regulatory norms and commitment to fair disclosure for investors.

This scheduled engagement highlights Zota Health Care’s ongoing efforts to maintain active dialogue with the investment community, which can support market understanding of its business performance and strategy. By emphasizing compliance with disclosure regulations and restricting discussions to publicly available materials, the company aims to ensure a level playing field for all shareholders and preserve the integrity of its communications with the market.

Zota Health Care Launches ‘All Day Stores’ Retail Chain to Deepen Consumer Reach

Zota Health Care Ltd. has expanded its consumer-facing portfolio by launching a new national retail chain, All Day Stores, through its subsidiary Everyday Herbal Beauty Care Limited. The format will focus on private-label offerings spanning personal care, household essentials, cosmetics, OTC, ayurvedic, surgical, and nutraceutical products, with each outlet stocking more than 430 SKUs at value-oriented prices.

In the first phase, the company plans to open 50 All Day Stores across key Indian markets, with around 15 outlets slated to launch on March 7, 2026, in Gujarat, West Bengal, Maharashtra, Karnataka, and Delhi. Management expects this forward-integration move to complement its established generic medicine retail network, enhance brand visibility, deepen consumer engagement, and support long-term growth and value creation for stakeholders.

Zota Health Care Grants Fifth ESOP Tranche to Employees

Zota Health Care Ltd. has granted 16,394 stock options to eligible employees under its Zota Health Care – Employee Stock Option Plan 2022, approved in line with SEBI’s share-based employee benefit regulations. The options, representing an equal number of equity shares of ₹10 each, will vest in three tranches over five years, with a seven-year exercise window from each vesting date, and form part of a broader ESOP pool of up to 250,000 options, of which 127,124 have been granted cumulatively so far.

This latest fifth tranche grant, bringing total unexercised options under the plan to 123,124 after cancellations, underscores the company’s ongoing use of stock-based compensation to align employee interests with long-term shareholder value. The structure of the vesting schedule and face-value exercise pricing suggests a focus on retention and incentivizing sustained performance, without any immediate impact on diluted earnings per share as no options have yet been exercised.

Zota Health Care Sets February 5 Earnings Call for Q3 FY26 Results

Zota Health Care Ltd. has scheduled an earnings conference call to discuss its financial performance for the third quarter and nine months ended December 31, 2025, following the planned announcement of results on February 4, 2026. The call, to be held on February 5, 2026 at 12:00 IST with participation from key members of the management team, underscores the company’s efforts to maintain transparent communication with investors and stakeholders regarding its operational and financial progress.

Zota Health Care Successfully Completes Qualified Institutions Placement

Zota Health Care Limited has announced the successful closure of its Qualified Institutions Placement (QIP), raising funds through the issuance of 22,80,130 equity shares to eligible institutional buyers at a determined price of ₹1,535 per share. This strategic move underscores the company’s commitment to strengthening its financial base to pursue growth opportunities, potentially boosting its market position and offering value to stakeholders.

Zota Health Care Concludes ₹1,535/share QIP Fundraising

Zota Health Care Limited has successfully concluded its Qualified Institutions Placement (QIP) of equity shares, raising funds by allocating 22,80,130 equity shares to qualified institutional buyers at ₹1,535 per share, inclusive of a premium. This strategic move will bolster the company’s financial capabilities, potentially enhancing its market positioning and operational initiatives within the competitive healthcare sector.

Zota Health Care Ltd. Raises ₹350 Crore via Qualified Institutions Placement

Zota Health Care Ltd. announced the successful completion of a Qualified Institutions Placement (QIP), resulting in the allotment of 2,280,130 equity shares to qualified institutional buyers at an issue price of ₹1,535 per share. This capital raise, totaling approximately ₹350 crore, increases the company’s paid-up equity share capital and provides financial resources for future operations and market growth, enhancing its market visibility in the healthcare sector.